EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Food and feed safety, innovation
Animal nutrition, veterinary medicines

VETPHARM 344

DRAFT AGENDA

22nd meeting of the Veterinary Pharmaceutical Committee
4 July 2016 (10:00-17:00)

Conference Centre Albert Borschette (CCAB)
room AB-1B
Rue Froissart 36
BE-1040 Brussels, Belgium

1. Opening and adoption of the agenda.

2. Maximum residue limits – discussion on draft implementing measures to the Regulation (EC) No 470/2009:

   a) draft Commission Implementing Regulation on the form and content of the applications and requests referred to in Articles 3 and 9 of the Regulation (EC) No 470/2009;

   b) draft Commission Regulation implementing Regulation (EC) No 470/2009 with regard to the rules on the use of a maximum residue limit established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or a maximum residue limit established for a pharmacologically active substance in one or more species for other species;

   c) update on the planned Commission implementing measure regarding the methodological principles for the risk assessment and risk management recommendations referred to in Articles 6 and 7 of Regulation (EC) No 470/2009, including technical requirements in accordance with internationally agreed standards.

3. Maximum residue limits – state of play and exchange of views on draft implementing measures to the Regulation (EC) No 470/2009:

   a) draft Commission Regulation on the maximum residue limits to be considered for control purposes for foodstuffs derived from animals which have been treated under Article 11 of Directive 2001/82/EC of the European Parliament and of the Council;

b) draft Commission Regulation on reference points for action for non-allowed pharmacologically active substances present in food of animal origin.

4. Maximum residue limits –update on latest developments.

5. Follow up to the discussion on diclofenac:

   a) Member State's update on the measures taken by the Member States at national level, including in particular information on reported vulture deaths in the Member States that have diclofenac authorised;

   b) discussion on the state of play and possible further steps.

6. Follow up to the discussion on gentamicin:

   a) outcome of the consultation with the Member States on the implementation into the national legislation of Article 6(3) of Directive 2001/82/EC;

   b) veterinary medicinal products for animals of the equidae family – situation in the Member States.

7. Notice to applicants Volume 6A: latest developments.

8. AOB